Financial Results Releases, Succession Plans, and New Appointments to Board of Directors - Research Report on ResMed, Sirona, Align, ABIOMED, and Globus

NEW YORK, August 7, 2013 /PRNewswire/ --

Today, Investors' Reports announced new research reports highlighting ResMed Inc. (NYSE: RMD), Sirona Dental Systems, Inc. (NASDAQ: SIRO), Align Technology, Inc. (NASDAQ: ALGN), ABIOMED, Inc. (NASDAQ: ABMD), and Globus Medical, Inc. (NYSE: GMED). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

ResMed Inc. Research Report

On August 1, 2013, ResMed, Inc. (ResMed) reported financial results for Q4 FY 2013 and full-year FY 2013. The Company's Q4 FY 2013 revenue was $414.6 million, up 11.5% YoY. Q4 FY 2013 non-GAAP operating income was $110.9 million, up 23.6% YoY, while non-GAAP net income was $90.7 million, up 18.1% YoY. Non-GAAP diluted EPS were $0.62, up 17.0% YoY. For full-year FY 2013, the Company generated revenues of $1.5 billion, up 10.7% YoY; non-GAAP operating income of $379.6 million, up 28.9% YoY; and non-GAAP diluted EPS of $2.22, up 29.8% YoY. Commenting on the results, Mick Farrell, CEO of ResMed said, "In the fourth quarter of fiscal 2013 we showed strong year-over-year growth on both top and bottom lines. We have also announced today that our quarterly dividend has increased by 47% to $0.25 per share. Additionally, during the quarter, we repurchased 1.5 million shares, at a cost of $72.7 million." The Full Research Report on ResMed Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-08-05/RMD]

--

Sirona Dental Systems, Inc. Research Report

On August 2, 2013, Sirona Dental Systems, Inc. (Sirona) announced that its Board of Directors has unanimously approved a succession plan for the CFO of the Company. The Company informed that Ulrich Michel will be joining Sirona as its CFO and Executive Vice President, effective October 14, 2013, and will be succeeding Simone Blank, who will step down as CFO, Executive Vice President, and Board member of the Company. According to Sirona, Michel will be responsible for overseeing and directing all aspects of the financial management of the Company as its CFO and Executive Vice President. Prior to joining Sirona, Michel was the CFO of WABCO for over eight years. The Full Research Report on Sirona Dental Systems, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-08-05/SIRO]

--

Align Technology, Inc. Research Report

On July 30, 2013, Align Technology, Inc. (Align) announced that it has appointed Andrea L. Saia to its Board of Directors. The Company informed that she will serve as a member of the audit committee. Commenting on the appointment, Thomas M. Prescott, President and CEO of Align said, "Her deep knowledge of healthcare, medical device, and consumer products industries combined with a strong marketing background from leading consumer companies such as Procter & Gamble, Unilever, and Revlon is a great fit for Align and will greatly contribute to our Invisalign business." Prior to joining the Company, Saia was the global head of Vision Care in the Alcon division of Novartis AG. The Full Research Report on Align Technology, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-08-05/ALGN]

--

ABIOMED, Inc. Research Report

On August 1, 2013, ABIOMED, Inc. (ABIOMED) reported Q1 FY 2014 (period ended June 30, 2013) financial results. In Q1 FY 2014, the Company generated revenues of $42.7 million, up 10.0% YoY. Q1 FY 2014 GAAP net loss was $1.7 million, or a loss of $0.04 per diluted share, compared with GAAP net income of $3.1 million, or $0.08 per diluted share in Q1 FY 2013. "We are on track to achieve our fiscal year revenue guidance and set new records in patient utilization," said Michael R. Minogue, Chairman, President, and CEO of ABIOMED. "We are pleased to report today that the FDA has recently approved our PMA Shell for our Impella modular submission." For full-year FY 2014, the Company maintained its revenue guidance in the range of $180 million to $185 million. The Company revised its full-year FY 2014 GAAP operating margin guidance, which is now expected to be approximately breakeven to 5%, lower than the previously announced guidance of 7% to 8%. The Full Research Report on ABIOMED, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-08-05/ABMD]

--

Globus Medical, Inc. Research Report

On August 1, 2013, Globus Medical, Inc. (Globus) reported its Q2 2013 financial results. In Q2 2013, the Company's worldwide sales amounted to $107.0 million, up 11.5% YoY. Net income for Q2 2013 was $7.4 million, or $0.08 per diluted share, compared with $19 million, or $0.21 per diluted share in Q2 2012. For full-year 2013, Globus reiterated its revenue guidance to be approximately $432 million and non-GAAP diluted EPS, excluding provisions for litigation losses, to be approximately $0.81. The Full Research Report on Globus Medical, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-08-05/GMED]

----

EDITOR NOTES:

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is fact checked and produced on a best efforts basis and reviewed by a CFA. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at [email protected].
5. For any urgent concerns or inquiries, please contact us at [email protected].
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to [email protected] for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider has, through Chartered Financial Analysts, only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

SOURCE Investors' Reports